Bile Duct Cancer: Clinical Trials

93 trials for Bile Duct Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

32 completed, 25 unknown, 18 recruiting, 7 terminated. 28 Phase 2, 22 Not applicable, 17 Phase 1, 5 Phase 3, 4 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 228Completed 7, Unknown 7, Recruiting 6, Terminated 5, Active not recruiting 2, Not yet recruiting 1
Not applicable22Completed 7, Unknown 6, Recruiting 5, Active not recruiting 1, Enrolling by invitation 1, Not yet recruiting 1, Withdrawn 1
Phase 117Completed 7, Recruiting 3, Terminated 2, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Suspended 1
Phase 35Unknown 3, Completed 2
Phase 44Completed 3, Unknown 1

Follow Bile Duct Cancer: new trials by email Literature Review of Bile Duct Cancer trials Research Report on Bile Duct Cancer

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)
Music-assisted relaxation and imagery (MARI) - Surgery, Stomach Cancer
Not applicableNot yet recruitingCase Comprehensive Cancer Center202027-01-012026-08-05
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
Endoscopic ultrasound examination - Pancreatic Disease, Pancreatic Cancer
Not applicableRecruitingOrlando Health, Inc.1402026-10-012026-10-20
Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer
Gemcitabin, Cisplatin and Durvalumab, Biliary Radiofrequency Ablation, Endoscopic Retrograde Cholangio-Pancreatography with stenting - Bile Duct Cancer
Phase 2RecruitingInsel Gruppe AG, University Hospital Bern362026-05-202026-05-26
Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas
Pancreaticojejunostomy with Modified N-Butyl-2-Cyanoacrylate (Glubran® 2), Standard(duct-to-mucosa) Pancreaticojejunostomy - Pancreatic Cancer, Periampullary Cancer
Not applicableRecruitingMinia University1942025-09-152026-10-01
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
Stereotactic Body Radiotherapy (SBRT), Tislelizumab, Gemcitabine - Cholangiocarcinoma, Hilar Cholangiocarcinoma
Phase 2RecruitingJinbo Yue382025-07-012026-10-15
A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors
KJ015 Injection (Subcutaneous Injection) - Gastric/Gastroesophageal Junction Cancer, Breast Cancer
Phase 1Not yet recruitingShanghai Bao Pharmaceuticals Co., Ltd.662025-06-242025-06-25
Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors
Utidelone Capsule 60mg/m2/d, Utidelone capsule 75mg/m2, Utidelone Capsule - Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer
Phase 2Not yet recruitingBeijing Biostar Pharmaceuticals Co., Ltd.1002024-12-012024-12-12
Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma
Intraductal biliary radiofrequency ablation - Cholangiocarcinoma, Klatskin Tumor
Not applicableRecruitingUniversitätsklinikum Hamburg-Eppendorf1302024-08-302026-09-09
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
oxaliplatin, capecitabine, Keytruda - Biliary Cancer, Bile Duct Cancer
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)602024-05-082026-10-30
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Gemcitabine, Cisplatin, Zimberelimab - Biliary Tract Carcinoma, Cholangiocarcinoma
Phase 2Active not recruitingNataliya Uboha332024-03-082026-08-17
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
UCMYM802 Injection - Malignant Mesothelioma, Colorectal Cancer
Phase 1UnknownUTC Therapeutics Inc.242024-03-052024-07-24
Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE)
Biliary Stricture, Bile Duct Cancer
RecruitingPeking University Third Hospital992024-03-012025-05-28
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Gemcitabine, Cisplatin, Durvalumab - Bile Duct Cancer, Cholangiocarcinoma
Phase 2RecruitingBeth Israel Deaconess Medical Center302024-02-132026-04-22
Looking At Bile Duct Cancer Patient Experience Patterns in Medical Trials
Bile Duct Cancer
UnknownPower Life Sciences Inc.5002024-02-012023-03-06
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
CEA-targeted CAR-T cells - Colorectal Cancer, Esophagus Cancer
Phase 1RecruitingChongqing Precision Biotech Co., Ltd302023-08-112023-09-21
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
AI-061 - Melanoma, Non Small Cell Lung Cancer
Phase 1CompletedOncoC4, Inc.182023-07-112026-09-14
Modified vs Conventional Blumgart Anastomosis of LPD for the Effects of Pancreatic Fistula of Periampullary Carcinoma
Modified Blumgart Anastomosis in LPD, conventional Blumgart anastomosis in LPD - Ampullary Cancer, Bile Duct Cancer
Not applicableEnrolling by invitationAffiliated Hospital of Guangdong Medical University1502023-07-012023-10-10
Combined Treatment of Treated Bile Duct Cancer
envolizumab , sovalteinib - Bile Duct Cancer
Phase 2UnknownZhejiang Cancer Hospital302023-07-012023-06-22
A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)
Solid Tumor, Advanced Solid Tumor
RecruitingCentro di Riferimento Oncologico - Aviano7822023-05-262023-09-13
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
certepetide, Durvalumab, Cisplatin - Cholangiocarcinoma, Gallbladder Cancer
Phase 2CompletedLisata Therapeutics, Inc.662023-05-132026-09-28

Showing 20 of 93. Sign in to see all of them.

Narrower conditions

Bile Duct Neoplasms (93)  ·  Pancreatic Neoplasms (49)  ·  Cholangiocarcinoma (32)  ·  Stomach Neoplasms (20)  ·  Gallbladder Neoplasms (18)  ·  Colorectal Neoplasms (17)  ·  Liver Neoplasms (17)  ·  Duodenal Neoplasms (12)  ·  Esophageal Neoplasms (12)  ·  Breast Neoplasms (11)  ·  Ovarian Neoplasms (11)  ·  Colonic Neoplasms (10)  ·  Rectal Neoplasms (10)  ·  Biliary Tract Neoplasms (9)  ·  Carcinoma, Hepatocellular (9)

Broader conditions

Biliary Tract Diseases (93)  ·  Digestive System Diseases (93)  ·  Neoplasms by Site (93)  ·  Digestive System Neoplasms (92)  ·  Bile Duct Diseases (90)  ·  Neoplasms (88)  ·  Biliary Tract Neoplasms (84)  ·  Endocrine Gland Neoplasms (54)  ·  Endocrine System Diseases (54)  ·  Neoplasms by Histologic Type (49)  ·  Neoplasms, Glandular and Epithelial (48)  ·  Pancreatic Diseases (46)  ·  Carcinoma (45)  ·  Adenocarcinoma (41)  ·  Gastrointestinal Diseases (39)

Interventions

Gemcitabine (10)  ·  Cisplatin (9)  ·  durvalumab (6)  ·  pembrolizumab (6)  ·  Oxaliplatin (5)  ·  Fluorouracil (4)  ·  Capecitabine (3)  ·  1-phenyl-3,3-dimethyltriazene (2)  ·  Leucovorin (2)  ·  Liver Transplantation (2)  ·  Long-Term Synaptic Depression (2)  ·  Pancreaticoduodenectomy (2)  ·  Radiosurgery (2)  ·  Stents (2)  ·  ceralasertib (2)

Sponsors

National Cancer Institute (NCI) (6)  ·  Seoul National University Hospital (5)  ·  Weill Medical College of Cornell University (4)  ·  Chiba University (2)  ·  Johannes Vermehren (2)  ·  Wakayama Medical University (2)  ·  Affiliated Hospital of Guangdong Medical University (1)  ·  Ajou University School of Medicine (1)  ·  Akita University Hospital (1)  ·  Anne Noonan (1)  ·  Beijing Biostar Pharmaceuticals Co., Ltd. (1)  ·  Beth Israel Deaconess Medical Center (1)  ·  Carisma Therapeutics Inc (1)  ·  Case Comprehensive Cancer Center (1)  ·  Cedars-Sinai Medical Center (1)

Countries

United States (38)  ·  China (10)  ·  South Korea (8)  ·  Germany (6)  ·  Australia (5)  ·  Canada (5)  ·  Japan (5)  ·  France (4)  ·  Sweden (3)  ·  Denmark (2)  ·  Italy (2)  ·  Spain (2)  ·  Austria (1)  ·  Belgium (1)  ·  Brazil (1)

Top investigators

Michel Kahaleh, MD (5)  ·  Tim F Greten, M.D. (4)  ·  Jonathan M Hernandez, M.D. (2)  ·  Katsunori Furukawa, MD (2)  ·  Ali A Aghdassi, Professor (1)  ·  Andrada Seicean, Professor (1)  ·  Andrea Bullock, MD, MPH (1)  ·  Anne M Noonan, MBBChBAO, MSc (1)  ·  Anthony El-Khoueiry, M.D. (1)  ·  Anthony J. Olszanski, M.D., RPh (1)  ·  Antoine Adenis, MD, PhD (1)  ·  Antonio Vigano, MD, MSc (1)  ·  Ari D Baron, MD (1)  ·  Arlette Da Silva, MD (1)  ·  Bert Hildebrandt, MD (1)

Results publications

PMID 17707751, PMID 20074698, PMID 21034892, PMID 21248633, PMID 24589090, PMID 25033929, PMID 25952086, PMID 26850262, PMID 26965712, PMID 27004243, PMID 27059973, PMID 27237786, PMID 27328985, PMID 27460387, PMID 28040257, PMID 28192597, PMID 29149611, PMID 29342492, PMID 29362244, PMID 30209610, PMID 30943124, PMID 31272934, PMID 31682550, PMID 31980466, PMID 32359091, PMID 32740096, PMID 32878766, PMID 32919526, PMID 33104917, PMID 33142018, PMID 33836153, PMID 34662180, PMID 34990208, PMID 34995788, PMID 35114169, PMID 35274717, PMID 35361487, PMID 35588692, PMID 35680043, PMID 35777186, PMID 35835611, PMID 36399037, PMID 36441083, PMID 36748723, PMID 38195752, PMID 38205877, PMID 38701690, PMID 38989414, PMID 39090600, PMID 39526177

NIH funding

2015 (2), 2023 (1), K07CA118576 (1), R01CA252211 (1)